Michael Bauer1, Andrea Pfennig. 1. Charité-University Medicine Berlin, Campus Charité Mitte (CCM), Department of Psychiatry and Psychotherapy, Berlin, Germany. michael.bauer@charite.de
Abstract
UNLABELLED: Bipolar, or manic-depressive, disorders are frequent and severe mental illnesses associated with considerable morbidity and mortality. Epilepsy and bipolar disorder could probably share some aspects of pathophysiology because manic as well as depressive symptoms are seen in patients with seizures, and a number of antiepileptic drugs are effectively used in the acute and prophylactic treatment of bipolar disorder. Epidemiologic research suggests a dimensional composition of bipolar illness at the population level. Apart from the DSM-IV diagnostic features of bipolar I (mania and depression) and bipolar II (hypomania and depression), the concept of bipolar spectrum disorders comprises a range of bipolar conditions with less obvious manifestations with estimated lifetime prevalence rates ranging from 2.8 to 6.5%. Expanding the definition of bipolar II disorders shows that half of the patients currently diagnosed with a unipolar depressive episode could suffer from unrecognized bipolar II disorder, and about the same number of mild depressive patients could be minor bipolars. Research efforts to refine the diagnostic criteria of bipolar disorder aim at an earlier and complete recognition of the disease to provide appropriate pharmacological and nonpharmacological treatment early in the course of the illness to anticipate individual suffering, suicidal behavior, and increased socioeconomic costs for society. This article also discusses risk factors, comorbid conditions, course of illness, as well as the individual and socioeconomic impact of bipolar disorders. CONCLUSIONS: The findings suggest reconceptualizing bipolar illnesses as highly recurrent, malignant disorders that occur far more frequently than previously thought. Interdisciplinary knowledge transfer could help to increase our understanding of the pathophysiology of these disorders as well as provide grounds for better recognition and treatment of patients with manic and/or depressive symptoms.
UNLABELLED: Bipolar, or manic-depressive, disorders are frequent and severe mental illnesses associated with considerable morbidity and mortality. Epilepsy and bipolar disorder could probably share some aspects of pathophysiology because manic as well as depressive symptoms are seen in patients with seizures, and a number of antiepileptic drugs are effectively used in the acute and prophylactic treatment of bipolar disorder. Epidemiologic research suggests a dimensional composition of bipolar illness at the population level. Apart from the DSM-IV diagnostic features of bipolar I (mania and depression) and bipolar II (hypomania and depression), the concept of bipolar spectrum disorders comprises a range of bipolar conditions with less obvious manifestations with estimated lifetime prevalence rates ranging from 2.8 to 6.5%. Expanding the definition of bipolar II disorders shows that half of the patients currently diagnosed with a unipolar depressive episode could suffer from unrecognized bipolar II disorder, and about the same number of mild depressivepatients could be minor bipolars. Research efforts to refine the diagnostic criteria of bipolar disorder aim at an earlier and complete recognition of the disease to provide appropriate pharmacological and nonpharmacological treatment early in the course of the illness to anticipate individual suffering, suicidal behavior, and increased socioeconomic costs for society. This article also discusses risk factors, comorbid conditions, course of illness, as well as the individual and socioeconomic impact of bipolar disorders. CONCLUSIONS: The findings suggest reconceptualizing bipolar illnesses as highly recurrent, malignant disorders that occur far more frequently than previously thought. Interdisciplinary knowledge transfer could help to increase our understanding of the pathophysiology of these disorders as well as provide grounds for better recognition and treatment of patients with manic and/or depressive symptoms.
Authors: David G Angeler; Brian C Chaffin; Shana M Sundstrom; Ahjond Garmestani; Kevin L Pope; Daniel R Uden; Dirac Twidwell; Craig R Allen Journal: Ecol Soc Date: 2020-01-01 Impact factor: 4.403
Authors: Ronald C Kessler; Hagop S Akiskal; Jules Angst; Margaret Guyer; Robert M A Hirschfeld; Kathleen R Merikangas; Paul E Stang Journal: J Affect Disord Date: 2006-09-25 Impact factor: 4.839
Authors: Heike Weber; Sarah Kittel-Schneider; Alexandra Gessner; Katharina Domschke; Maria Neuner; Christian P Jacob; Henriette N Buttenschon; Andrea Boreatti-Hümmer; Julia Volkert; Sabine Herterich; Bernhard T Baune; Silke Gross-Lesch; Juliane Kopf; Susanne Kreiker; Thuy Trang Nguyen; Lena Weissflog; Volker Arolt; Ole Mors; Jürgen Deckert; Klaus-Peter Lesch; Andreas Reif Journal: Neuropsychopharmacology Date: 2011-06-08 Impact factor: 7.853
Authors: Lena Weißflog; Nils Becker; Nelli Bossert; Florian Freudenberg; Sarah Kittel-Schneider; Andreas Reif Journal: Eur Arch Psychiatry Clin Neurosci Date: 2016-04-16 Impact factor: 5.270
Authors: Michael Bauer; Georg Juckel; Christoph U Correll; Karolina Leopold; Andrea Pfennig Journal: Eur Arch Psychiatry Clin Neurosci Date: 2008-11 Impact factor: 5.270
Authors: Kathleen R Merikangas; Hagop S Akiskal; Jules Angst; Paul E Greenberg; Robert M A Hirschfeld; Maria Petukhova; Ronald C Kessler Journal: Arch Gen Psychiatry Date: 2007-05